Summary
Adjuvant therapies are increasingly used in colorectal cancers for the prevention of recurrence. These therapies have side-effects and should, thus, be used only if really beneficial. However, the development of recurrence cannot be predicted reliably at the moment of diagnosis, and targeting of adjuvant therapies is thus based only on the primary stage of the cancer. Loss of heterozygosity (LOH) in the long arm of chromosome 18 is suggested to be related to poor survival and possibly to the development of metastases. We studied the value of LOH at 18q21 as a marker of colorectal cancer prognosis, association with clinicopathological variables, tumour recurrence and survival of the patients. Of the 255 patients studied, 195 were informative as regards LOH status when analysed in primary colorectal cancer specimens using the polymerase chain reaction (PCR) and fragment analysis. LOH at 18q21 was significantly associated with the development of recurrence (P= 0.01) and indicated poor survival in patients of Dukes’ classes B and C, in which most recurrences (82%) occurred. An increased rate of tumour recurrence is the reason for poor survival among patients with LOH at 18q21 in primary cancer. These patients are a possible target group for recurrence-preventing adjuvant therapies.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arveux, I., Boutron, M. C., Arveux, P., Liabeuf, A., Pfitzenmeyer, P. & Faivre, J. (1997). Colon cancer in the elderly: evidence for major improvements in health care and survival. Br J Cancer 76: 963–967.
Cawkwell, L., Bell, S. M., Lewis, F. A., Dixon, M. F., Taylor, G. R. & Quirke, P. (1993). Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer 87: 1262–1267.
Dib, C., Faure, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Hazan, J., Seboun, E., Lathrop, M., Gyapay, G., Morissette, J. & Weissenbach, J. (1996). A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature 380: 152–154.
Elo, J. P., Kvist, L., Leinonen, K., Isomaa, V., Henttu, P., Lukkarinen, O. & Vihko, P. (1995). Mutated human androgen-receptor gene detected in a prostatic-cancer patient is also activated by estradiol. J Clin Endocrinol Metab 80: 3494–3500.
Eppert, K., Scherer, S. W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L-C, Bapat, B., Gallinger, S., Andrulis, I. L., Thomsen, G. H., Wrana, J. L. & Attisano, L. (1996). MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86: 543–552.
Fearon, E. R., Cho, K. R., Nigro, J. M., Kern, S. E., Simons, J. W., Ruppert, J. M., Hamilton, S. R., Preisinger, A. C., Thomas, G., Kinzler, K. W. & Vogelstein, B. (1990). Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247: 49–56.
Fielding, L. P., Hittinger, R., Grace, R. H. & Fry, J. S. (1992). Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 340: 502–506.
Frank, C. J., McClatchey, K. D., Devaney, K. O. & Carey, T. E. (1997). Evidence that loss of chromosome 18q is associated with tumor progression. Cancer Res 57: 824–827.
Hedrick, L., Cho, K. R., Fearon, E. R., Wu, T-C, Kinzler, K. W. & Vogelstein, B. (1994). The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 8: 1174–1183.
Iino, H., Fukayama, M., Maeda, Y., Koike, M., Mori, T., Takahashi, T., Kikuchi-Yanoshita, R., Miyaki, M., Mizuno, S. & Watanabe, S. (1994). Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential. Cancer 73: 1324–1331.
Jass, J. R. & Sobin, L. H. (1989). Histological typing of intestinal tumors. In World Health Organization. International Classification of Tumors, 2nd edn: Springer: Berlin
Jen, J., Kim, H., Piantadosi, S., Liu, Z-F, Levitt, R. C., Sistonen, P., Kinzler, K. W., Vogelstein, B. & Hamilton, S. R. (1994). Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331: 213–221.
Jernvall, P., Mäkinen, M., Karttunen, T., Mäkelä, J. & Vihko, P. (1997). Conserved area mutations of the p53 gene are concentrated in distal colorectal cancers. Int J Cancer (Pred Oncol) 74: 97–101.
Kato, M., Ito, Y., Kobayashi, S. & Isono, K. (1996). Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Cancer 77: 1729–1735.
Kikuchi-Yanoshita, R., Konishi, M., Fukunari, H., Tanaka, K. & Miyaki, M. (1992). Loss of expression of the DCC gene during progression of colorectal carcinomas in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 52: 3801–3803.
Mäkelä, J. T., Laitinen, S. T. & Kairaluoma, M. I. (1995). Five-year follow-up after radical surgery for colorectal cancer. Arch Surg 130: 1062–1067.
Obrand, D. I. & Gordon, P. H. (1997). Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 40: 15–24.
O’Connell, M. J., Schaid, D. J., Ganju, V., Cunningham, J., Kovach, J. S. & Thibodeau, S. N. (1992). Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis? Cancer 70: 1732–1739.
Ponz de Leon, M., Sant, M., Micheli, A., Sacchetti, C., Digregorio, C., Fante, R., Zanghieri, G., Melotti, G. & Gatta, G. (1992). Clinical and pathological prognostic indicators in colorectal cancer. Cancer 69: 626–635.
Sant, M., Capocaccia, R., Verdecchia, A., Gatta, G., Micheli, A., Mariotto, A., Hakulinen, T. & Berrino, F. The Eurocare Working Group (1995). Comparisons of colon-cancer survival among European countries: The Eurocare Study. Int J Cancer 63: 43–48.
Swedish Rectal Cancer Trial (1996). Local recurrence rate in a randomised multicentre trial of preoperative radiotherapy compared with operation alone in resectable rectal carcinoma. Eur J Surg 162: 397–402.
Thiagalingam, S., Lengauer, C., Leach, F. S., Schutte, M., Hahn, S. A., Overhauser, J., Willson, J. K. V., Markowich, S., Hamilton, S. R., Kern, S. E., Kinzler, K. W. & Vogelstein, B. (1996). Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nature Genet 13: 343–346.
Turnbull, R. B., Kyle, K., Watson, F. R. & Spratt, J. (1967). Cancer of colon: the influence of the no-touch isolation technic on survival rates. Ann Surg 166: 420–427.
Vernava, A. M., Longo, W. E., Virgo, K. S., Coplin, M. A., Wade, T. P. & Johnson, F. E. (1994). Current follow-up strategies after resection of colon cancer. Results of a survey of members of the American Society of Colon and Rectal Surgeons. Dis Colon Rectum 37: 573–583.
Wright, D. K. & Manos, M. M. (1990). Sample preparation from paraffin-embedded tissues. In PCR Protocols: A Guide to Methods and Applications, Innis MA, Gelfand DH, Sninsky JJ, White TJ (eds), pp. 153–158, Academic Press: San Diego
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Jernvall, P., Mäkinen, M., Karttunen, T. et al. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 79, 903–908 (1999). https://doi.org/10.1038/sj.bjc.6690144
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690144
Keywords
This article is cited by
-
Interpreting the Inconsistent Data Concerning the Role of 18qLOH as a Prognostic Marker for Colorectal Cancer
Current Colorectal Cancer Reports (2010)
-
Adjuvant chemotherapy after neoadjuvant chemoradiation and surgery: A quest to improve survival for stage II and III rectal cancer
Current Colorectal Cancer Reports (2009)
-
Preoperative Serum Vascular Endothelial Growth Factor-A Is a Marker for Subsequent Recurrence in Colorectal Cancer Patients
Diseases of the Colon & Rectum (2009)
-
Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis
International Journal of Colorectal Disease (2007)
-
Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: a study matched for T- and N- classification
British Journal of Cancer (2006)